Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

Dementia and Geriatric Cognitive Disorders

Volumn 41, Issue 1-2, 2016, Pages 80-92

  Grundman, Michael ^a,b   Johnson, Keith A ^c   Lu, Ming ^d   Siderowf, Andrew ^d   Dellagnello, Grazia ^e   Arora, Anupa K ^d   Skovronsky, Daniel M ^d   Mintun, Mark A ^d   Pontecorvo, Michael J ^d  

^a Global R and D Partners LLC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Appropriate use criteria; Florbetapir; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; FLORBETAPIR F 18; MEMANTINE; AMYLOID; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; COGNITIVE DEFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PATIENT CARE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; COGNITION; COMPARATIVE STUDY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; COGNITION; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84954419018     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000441139     Document Type: Article

References (30)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
3. Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;71:266-273.
4. Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gomez-Isla T, Betensky RA, Growdon JH, Johnson KA, Frosch MP, Sperling RA, Hyman BT: Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014;75:597-601.
5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurology 2004;55:306-319.
6. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-135.
7. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-1259.
8. 18F-AV-45 (florbetapir F 18). J Nucl Med 2010;51:913-920.
9. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Saha K, Burns JD: Lowrey MJ, Mintun MA, Skovronsk DM; Florbetapir F 18 Study Investigators: Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-384.
10. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WG, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleischer AS, Sabbagh MN, Sadowsky CH, Reiman PEM, Zehntner SP, Skovronsky DM; AV45-A07 Study Group: Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 2011;305:275-283.
11. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman PEM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012;11:669-678.
12. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Wlaker Z, Hunjan A, Holmes C, Escovar YM, Vera, CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith APL, Buckley CJ, McLain R, Salloway S: Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015;72:287-294.
13. Leinonen V, Alafuzoff I, Aalto S, Suotunen, T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO: Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304-1309.
14. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group: Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement 2015;11:964-974.
15. Degerman Gunnarsson M, Lindau M, Santillo AF, Wall A, Engler H, Lannfelt L, Basun H, Kilander L: Reevaluation of clinical dementia diagnoses with Pittsburgh compound B positron emission tomography. Dement Geriatr Cogn Dis Extra 2013;3:472-481.
16. 11C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra 2012;2:610-621.
17. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; AV-45-A17 Study Group: Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013,27:4-15.
18. 18F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener 2014;9:10.
19. Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, Windhorst AD, Handels RL, Wolfs CA, Aalten P, Verhey FR, Verbeek MM, van Buchem MA, Hoekstra OS, Lammertsma AA, Scheltens P, van Berckel BN: Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013;9:414-421.
20. Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, O'Neil JP, Janabi M, Huang EJ, Trojanowski JQ, Vinters HV, Gorno-Tempini M, Seeley WW, Boxer AL, Rosen HJ, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD: Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 2014;82:230-238.
21. Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, Hock C, Kunz M, Kuhlmann J, Reininger C, Blankenburg M: Impact of β-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:416-422.
22. Johnson KA, Minoshima S, Bohnen NI, Donohue KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Dual publication in: Alzheimers Dement 2013;9:e-1-16 and J Nucl Med 2013;54:476-490.
23. Johnson KA, Minoshima S, Bohnen NI, Donohue KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013;54:476-490.
24. Royal College of Physicians and Royal College of Radiologists: Evidence-Based Indications for the Use of PET-CT in the UK. London, RCP/RCR, 2013.
25. Guerra UP, Nobili FM, Padovani A, Perani D, Pupi A, Sorbi S, Trabucchi M: Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci 2015;36:1075-1081.
26. Roman GC, Salloway S, Black SE, Royall DR, DiCarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H: Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41:1213-1221.
27. Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group: Florbetapir F 18 amyloid PET and longitudinal cognitive decline: a prospective 36-month multicenter study. Mol Psychiatry 2014;19:1044-1051.
28. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC; AIBL Research Group: Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014;137:221-231.
29. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-1283.
30. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-329.